280 related articles for article (PubMed ID: 12063863)
1. [Acromegaly associated with McCune-Albright syndrome].
Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
[TBL] [Abstract][Full Text] [Related]
2. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
3. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Laczi F; Magony S; Julesz J
Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
5. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
6. McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
Almeida JP; Albuquerque LA; Ferraz CL; Mota I; Gondim J; Ferraz TM
Arq Bras Endocrinol Metabol; 2009 Feb; 53(1):102-6. PubMed ID: 19347192
[TBL] [Abstract][Full Text] [Related]
7. Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone?
Hannon TS; Noonan K; Steinmetz R; Eugster EA; Levine MA; Pescovitz OH
J Pediatr; 2003 May; 142(5):532-8. PubMed ID: 12756386
[TBL] [Abstract][Full Text] [Related]
8. Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201-995--bromocriptine combined treatment results.
Cremonini N; Graziano E; Chiarini V; Sforza A; Zampa GA
J Clin Endocrinol Metab; 1992 Oct; 75(4):1166-9. PubMed ID: 1400888
[TBL] [Abstract][Full Text] [Related]
9. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
10. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
Esposito V; Esposito D; Lo Iudice G
Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
[TBL] [Abstract][Full Text] [Related]
11. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
[TBL] [Abstract][Full Text] [Related]
12. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
13. The Albright syndrome associated with acromegaly: report of a case and review of the literature.
Lipson A; Hsu TH
Johns Hopkins Med J; 1981 Jul; 149(1):10-4. PubMed ID: 7019531
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome.
Yao Y; Liu Y; Wang L; Deng K; Yang H; Lu L; Feng F; Xing B; You H; Jin Z; Wang R; Pan H; Chen S; Zhu H
Eur J Endocrinol; 2017 Mar; 176(3):295-303. PubMed ID: 28007843
[TBL] [Abstract][Full Text] [Related]
15. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients.
Galland F; Kamenicky P; Affres H; Reznik Y; Pontvert D; Le Bouc Y; Young J; Chanson P
J Clin Endocrinol Metab; 2006 Dec; 91(12):4957-61. PubMed ID: 16984995
[TBL] [Abstract][Full Text] [Related]
16. Acromegaly with fibrous dysplasia: McCune-Albright Syndrome -- clinical studies in 3 cases and brief review of literature--.
Bhansali A; Sharma BS; Sreenivasulu P; Singh P; Vashisth RK; Dash RJ
Endocr J; 2003 Dec; 50(6):793-9. PubMed ID: 14709853
[TBL] [Abstract][Full Text] [Related]
17. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
Harinarayan CV
J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
[TBL] [Abstract][Full Text] [Related]
18. Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.
Bałdys-Waligórska A; Krzentowska-Korek A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
Exp Clin Endocrinol Diabetes; 2011 May; 119(5):295-9. PubMed ID: 21264808
[TBL] [Abstract][Full Text] [Related]
19. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
Akintoye SO; Chebli C; Booher S; Feuillan P; Kushner H; Leroith D; Cherman N; Bianco P; Wientroub S; Robey PG; Collins MT
J Clin Endocrinol Metab; 2002 Nov; 87(11):5104-12. PubMed ID: 12414879
[TBL] [Abstract][Full Text] [Related]
20. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
Candrina R
Recenti Prog Med; 1994 Jan; 85(1):13-9. PubMed ID: 8184174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]